Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dextrose provides glucose for cellular metabolism, replenishing energy stores and correcting hypoglycemia. Sodium chloride and potassium chloride restore electrolyte balance, maintaining osmolality and membrane potentials.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Intravenous hydration and electrolyte replacement,Treatment of hypovolemia,Maintenance of fluid and electrolyte balance when oral intake is inadequate
Treatment of serious gram-negative bacterial infections,Septicemia,Lower respiratory tract infections,Intra-abdominal infections,Complicated urinary tract infections,Skin and soft tissue infections,Bone and joint infections,Burn infections,Perioperative prophylaxis in high-risk patients
Intravenous infusion. Typical adult dose: 1000 m L to 2000 m L per 24 hours, administered at a rate of 50-100 m L/hour, adjusted based on fluid and electrolyte status.
15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).
Dextrose: Not applicable (endogenous). Potassium: Rapid distribution phase (1-1.5 h) with terminal half-life 12-24 h (dose-dependent due to intracellular uptake). Sodium and chloride: Governed by renal regulation, no true half-life.
Terminal elimination half-life: 2–3 hours in patients with normal renal function; may be prolonged to 30–60 hours in anuria.
Dextrose is metabolized to carbon dioxide and water via glycolysis and the citric acid cycle. Sodium and potassium are excreted primarily by the kidneys, with regulation by hormonal and renal mechanisms.
Primarily excreted unchanged by glomerular filtration. Minimal hepatic metabolism.
Renal: Dextrose is metabolized to CO2 and water, not excreted unchanged. Sodium and chloride are excreted renally (90-95% of filtered load reabsorbed). Potassium is excreted renally (90% of daily intake, with 10% fecal).
Renal excretion of unchanged drug via glomerular filtration; >90% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion <1%.
Dextrose: Not bound. Sodium: Not bound. Potassium: Not bound. Chloride: Not bound.
Low protein binding; 0–11% bound, primarily to albumin.
Dextrose: 0.2 L/kg (extracellular space). Sodium: 0.15-0.2 L/kg. Chloride: 0.15-0.2 L/kg. Potassium: 0.4-0.6 L/kg (total body water).
Vd: 0.25–0.4 L/kg; approximates extracellular fluid volume. Increased in edema, ascites; decreased in dehydration.
Intravenous: 100%.
Intravenous: 100% bioavailable. Not administered orally (negligible absorption).
For GFR 30-50 m L/min: reduce dose by 25%. For GFR 15-29 m L/min: reduce dose by 50%. For GFR <15 m L/min: avoid use or use with extreme caution, monitoring potassium levels closely.
For GFR 30-59 m L/min: extend interval to every 12-24 hours; GFR 15-29 m L/min: every 24-48 hours; GFR <15 m L/min (not on dialysis): every 48-96 hours or consider dosing based on serum levels.
No specific Child-Pugh based dose adjustment required, but monitor potassium levels in severe hepatic impairment due to risk of hyperkalemia.
No specific Child-Pugh based modifications; monitor renal function and drug levels.
Weight-based dosing: 5-10 m L/kg over 24 hours, not to exceed adult daily fluid requirements; potassium supplementation calculated as 1-3 m Eq/kg/day, titrated to serum levels.
Neonates: 15-20 mg/kg/day IV divided every 12 hours; Infants and Children: 15-22.5 mg/kg/day IV divided every 8-12 hours.
Start at lower end of dosing range; consider reduced initial infusion rate (50 m L/hour) and monitor renal function and potassium levels closely due to age-related decline in GFR and higher risk of hyperkalemia.
Adjust dose based on renal function; monitor serum creatinine and trough levels; usual starting dose: 15 mg/kg/day with extended intervals per renal function.
None
Aminoglycosides can cause nephrotoxicity and ototoxicity. Neurotoxicity (including vestibular and auditory) may occur even at normal doses. Risk is greater in patients with renal impairment, pre-existing hearing loss, or prolonged use. Monitor renal function and eighth cranial nerve function.
Risk of fluid and electrolyte imbalances, including hyperglycemia, hyperkalemia, hypokalemia, and hypernatremia,Monitor serum glucose, electrolytes, and fluid status closely,Avoid in patients with severe renal impairment or conditions predisposing to fluid overload,Use caution in patients with heart failure, pulmonary edema, or hepatic cirrhosis
Monitor renal function and audiometric tests,Adjust dose based on renal function,Risk of neuromuscular blockade, especially in patients with neuromuscular disorders,Avoid concurrent use of other nephrotoxic or ototoxic drugs,Use caution in neonates, elderly, and patients with dehydration
Hyperkalemia,Severe metabolic acidosis,Severe renal impairment (oliguria, anuria),Hypernatremia,Fluid overload states (e.g., pulmonary edema)
Hypersensitivity to amikacin or other aminoglycosides,Myasthenia gravis (relative due to risk of neuromuscular blockade)
No specific food interactions, but patients should avoid potassium-rich foods unless directed by the healthcare provider, as this solution already provides potassium.
No clinically significant food interactions. Maintain adequate hydration. Avoid excessive alcohol consumption.
No evidence of teratogenic risk from dextrose, sodium chloride, or potassium chloride at standard replacement doses. Electrolyte imbalances, if severe, could theoretically impair fetal development. First trimester: low risk. Second and third trimesters: low risk; caution with potassium administration to avoid maternal hyperkalemia, which may cause fetal bradycardia.
Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal ototoxicity (eighth cranial nerve damage) and nephrotoxicity, especially with high doses or prolonged use. Avoid unless compelling indication.
Dextrose, sodium chloride, and potassium chloride are normal constituents of breast milk. Administration of these components at replacement doses does not pose a risk to the nursing infant. M/P ratio not applicable as these are endogenous substances.
Minimal excretion into breast milk (M/P ratio unknown but expected low). No reports of adverse effects in nursing infants from maternal amikacin use. Caution with infant renal impairment or premature infants due to potential accumulation. Use only if necessary.
Pregnancy increases plasma volume and glomerular filtration rate; however, for this combination product used as a maintenance or replacement solution, standard dosing is generally appropriate. Monitor serum potassium closely as potassium requirements may increase due to increased renal losses. No dose adjustment for dextrose or sodium chloride unless specific deficits or excesses are identified.
Increased renal clearance in pregnancy may lower serum levels; consider higher doses based on therapeutic drug monitoring. Adjust for renal impairment if present. Standard initial dosing: 15 mg/kg/day IV/IM divided q8-12h, with level-guided adjustments.
This combination is indicated for maintenance fluid therapy when both sodium and potassium repletion are needed, particularly in patients with isotonic or hypotonic dehydration. Monitor serum potassium closely, especially in renal impairment. Do not administer rapidly; adjust rate based on fluid and electrolyte status. Contraindicated in hyperkalemia, hypernatremia, or severe renal failure. Use with caution in heart failure or edema.
Amikacin is an aminoglycoside antibiotic with concentration-dependent bactericidal activity. Monitor peak (20-30 mcg/m L) and trough (<10 mcg/m L) serum levels to optimize efficacy and minimize toxicity. Adjust dose based on renal function (Cr Cl). Ototoxicity (vestibular and cochlear) and nephrotoxicity are dose-limiting; audiometry and renal function tests are mandatory. Extended-interval dosing (15-20 mg/kg once daily) is preferred for most indications. Avoid concurrent use with other nephrotoxic drugs (e.g., vancomycin, loop diuretics).
This intravenous solution contains dextrose (sugar), sodium, and potassium to provide fluids and electrolytes.,Tell your healthcare provider if you have kidney disease, heart problems, or high potassium levels.,Report any symptoms like muscle weakness, irregular heartbeat, or swelling in your hands or feet.,Do not eat or drink without your doctor's approval while receiving this treatment.,This solution is typically given in a hospital; you will be monitored for fluid balance and electrolyte levels.
Take exactly as prescribed; do not skip doses or stop early.,Drink plenty of fluids to stay hydrated.,Report hearing changes (ringing in ears, dizziness) immediately.,Report decreased urine output or swelling in legs.,Avoid taking other medications without consulting your doctor, especially pain relievers like ibuprofen.,This medication is given intravenously; you may feel warmth or tingling during infusion.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER vs AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER is a Electrolyte that works by Dextrose provides glucose for cellular metabolism, replenishing energy stores and correcting hypoglycemia. Sodium chloride and potassium chloride restore electrolyte balance, maintaining osmolality and membrane potentials.. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER is: Intravenous infusion. Typical adult dose: 1000 m L to 2000 m L per 24 hours, administered at a rate of 50-100 m L/hour, adjusted based on fluid and electrolyte status.. The standard adult dose of AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours (usual adult dose: 15 mg/kg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER and AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER is classified as Category A/B. No evidence of teratogenic risk from dextrose, sodium chloride, or potassium chloride at standard replacement doses. Electrolyte imbalances, if severe, could theoretically impair f. AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Aminoglycosides like amikacin cross the placenta. First trimester: No evidence of major malformations, but risk cannot be excluded. Second and third trimesters: Potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.